Afatinib: Added benefit in certain mutations confirmed

Thursday, August 20, 2015 - 14:30 in Health & Medicine

In advanced non-small cell lung cancer, the new tyrosine-kinase inhibitor is more effective than combination chemotherapy in patients with certain mutations, reviewers report.

Read the whole article on Science Daily

More from Science Daily

Learn more about

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net